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Abstract
Background Postoperative ileus is a common condition after
abdominal surgery.Many prokinetic drugs have been evaluated
including osmotic laxatives. The data on colon-stimulating
laxatives are scarce. This prospective, randomized, double-
blind trial investigates the effect of the colon-stimulating
laxative bisacodyl on postoperative ileus in elective colorectal
resections.
Materials and methods Between November 2004 and
February 2007, 200 consecutive patients were randomly
assigned to receive either bisacodyl or placebo. Primary
endpoint was time to gastrointestinal recovery (mean time
to first flatus passed, first defecation, and first solid food
tolerated; GI-3). Secondary endpoints were incidence and
duration of nasogastric tube reinsertion, incidence of
vomiting, length of hospital stay, and visual analogue
scores for pain, cramps, and nausea.
Results One hundred sixty-nine patients were analyzed, and
31 patients discontinued the study. Groups were comparable
in baseline demographics. Time to GI-3 was significantly
shorter in the bisacodyl group (3.0 versus 3.7 days, P=
0.007). Of the single parameters defining GI-3, there was a
1-day difference in time to defecation in favor to the
bisacodyl group (3.0 versus 4.0 days, P=0.001), whereas
no significant difference in time to first flatus or tolerance
of solid food was seen. No significant difference in the
secondary endpoints was seen. Morbidity and mortality did
not differ between groups.
Conclusion Bisacodyl accelerated gastrointestinal recovery
and might be considered as part of multimodal recovery
programs after colorectal surgery.
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Introduction
Postoperative ileus, characterized by nausea, vomiting,
abdominal distension, and pain, occurs frequently following
abdominal surgery. It leads to patient discomfort, may
contribute to related complications and consequently to a
prolonged length of hospital stay. Multiple factors, including
surgical manipulation, inflammatory mediators, autonomic
dysfunction, electrolyte and fluid imbalances, and analgesics
(opioids) contribute to the etiology [1, 2].
Without specific treatment, postoperative ileus resolves
spontaneously within 4 to 5 days. Whereas small bowel and
stomach recover early, colonic motility is the last to return
[3–5]. Current treatment approaches involve minimally
invasive surgery and different multimodal rehabilitation
programs (fast track), including epidural analgesia,
enforced mobilization, early feeding, immediate removal
of catheters, curved or transverse incisions, and a variety of
prokinetic agents [6–10].
Several pharmacologic studies have been carried out to
evaluate the effect of different agents, such as metoclopra-
mide, erythromycin, tropisetron, alvimopan, neostigmine, and
cisapride on postoperative ileus [11–22]. Only cisapride,
which has been removed from the market for cardiac side
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effects, and alvimopan showed a significant acceleration of
gastrointestinal recovery [15, 16, 22].
Although there is evidence that the normalization of
colonic motility is the most decisive factor for full recovery
of gastrointestinal function, there are only two studies
evaluating the role of colon-stimulating laxatives on the
recovery of postoperative gastrointestinal function [23, 24].
The first is a prospective observational study and the
second is a randomized trial with 23 patients in each arm.
Both studies indicated an earlier return of bowel movement.
Bisacodyl is a laxative of the triarylmethane group,
which is hydrolyzed in the bowel by local enzymes into the
active agent bis-(p-hydroxyphenyl)-pyridyl-2-methane
(BHPM). BHPM directly stimulates colonic peristalsis.
The aim of this randomized, double-blind, placebo-
controlled trial was to investigate the effect of bisacodyl on
the duration of postoperative ileus in patients undergoing
elective colorectal resection.
Materials and methods
All adult patients (>18 years, <90 years) admitted for elective
open or laparoscopic colorectal resection at the Triemli
Hospital in Zurich, Switzerland, were evaluated for eligibility.
Exclusion criteria were: preoperatively planned protective
ileostomy or definite colostomy, emergency surgery, preg-
nancy, and known hypersensitivity for bisacodyl.
The trial was registered by the National Library of
Medicine at www.clinicaltrials.gov under the number
NCT00509327. The study was approved by the local ethics
committee and the Swiss Federal Agency for Therapeutic
Products (Swissmedic). Written informed consent was
obtained from each patient before enrolment in the study.
Study design
Patients were randomized using a computer system to
receive either 10 mg bisacodyl (Dulcolax®, Boehringer
Ingelheim, Switzerland) in an opaque capsule orally or
identical placebo capsules (glucosemonohydricum). Manu-
facturing of the capsules was done by the hospital
pharmacy. The capsules were administered twice daily,
beginning 1 day prior to surgery and ending on postoper-
ative day 3. Rationale for length of bisacodyl administration
was the fact that postoperative ileus has been shown to
resolve spontaneously by days 4 to 5. Patients and all
involved medical personnel were blinded.
Bowel preparation was not prescribed for open surgery,
whereas in patients undergoing laparoscopic resection, 2 l
of sodium sulfate/macrogol solution (Cololyt®, Spirig
Pharma AG, Switzerland) was administered. Thoracic
epidural analgesia was discussed with every patient. In the
absence of contraindications (previous back surgery, severe
spondylarthrosis, coagulopathy) and with agreement of the
patient, an epidural catheter was placed between Th 8 and
Th 12 at induction of anesthesia. Postoperatively, the
thoracic epidural catheter was left in situ and a solution
consisting of 48 ml 0.125% bupivacaine (Duracain®,
Sintetica, Mendrisio, Switzerland) with 2 ml fentanyl
(Fentanyl-Curamed®, Opopharma, Zurich, Switzerland)
was administered for continuous analgesia during the first
five postoperative days.
Standard colorectal surgery was performed in all
patients. We performed a midline incision for open surgery
and a four-port technique with removal of the specimen
through a small transverse incision in the lower abdomen
for laparoscopic procedures. All patients received perioper-
ative single shot antibiotics (cefuroxime 1.5 g and metro-
nidazole 1 g i.v.). The nasogastric tube (NGT) was removed
at the end of the operation.
All patients received a basic analgesia of 0.5 to 1 g
paracetamol (Dafalgan®, Bristol-Myers Squibb, Baar,
Switzerland) given orally every 6 h. For additional pain
relief, metamizol (Novalgin®, Sanofi-Aventis, Meyrin,
Switzerland) was used as first line reserve and morphine or
its derivates as second line reserve. Opioid consumption was
monitored during the first eight postoperative days. To allow
comparison between groups concerning consumption, all
opioids were converted to an equivalent morphine dose.
Nutrition was started on the first postoperative day. We
used a five-step diet protocol, starting with limited fluids
(1,000 ml/day), followed by free fluids, soft food, light
meals, and normal diet. The next step was given if patients
had bowel movement, no nausea, and tolerated the
previously given nutrition.
Data analysis
The primary endpoint was recovery of gastrointestinal
function, defined as the mean time to the occurrence of
the following events (GI-3): first flatus passed, first
defecation, and first solid food tolerated. We did not
include the presence of bowel sounds, as these may occur
due to small bowel activity and be present before colonic
recovery [25]. Secondary endpoints were the incidence and
duration of NGT reinsertion, incidence of postoperative
vomiting, and length of hospital stay. Indication for NGT
reinsertion was repetitive nausea or vomiting. Reinserted
NGT was left in situ until secretion was less than 100 ml
per 24 h. Additionally, consumption of analgesics was
documented and scores for pain, cramps, and nausea,
assessed by a standard visual analogue scale (VAS) during
the first eight postoperative days, were monitored [26].
GI-3 and VAS scores were obtained daily by the respon-
sible intern during the morning ward rounds. The VAS
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consisted of a 10-cm ruler with a scale from 0 (no pain) to
10 (highest imaginable pain). Other variables recorded were
patients’ demographics, use of epidural anesthesia, type and
duration of surgery, and morbidity.
Statistical analysis
A sample size of 80 patients in each group was calculated
assuming that the time to full gastrointestinal recovery (GI-3)
would be reached 20% earlier in the bisacodyl group
(4 versus 5 days in the placebo group) with a significance
of 5% and 90% power. To allow for dropouts, for example
due to preoperatively unexpected need for stoma, it was
planned to include a total number of 200 patients.
The groups were compared by means of the Mann–
Whitney U test for continuous data and the Fisher’s exact
test for non-continuous data. In case of normal distribution,
a Student’s t test was applied. A two-tailed P≤0.05 was
considered statistically significant. GraphPad InStat® version
3.06 (GraphPad Software Inc., San Diego, USA) was used for
statistical calculations.
Results
Of the 283 patients assessed for eligibility between
November 2004 and February 2007, 43 did not meet the
inclusion criteria (preoperative planned protective stoma
formation, extirpation of rectum with terminal stoma) and
40 refused to participate. Fourteen patients in the placebo
group and 17 in the bisacodyl group discontinued the study
(Fig. 1). The characteristics of the remaining 169 patients
are shown in Table 1. With the exception of a significant
difference in the surgery duration, groups were comparable in
baseline demographics and perioperative data. Rectosigmoid
resection (n=103, 60.9%) was most often performed,
followed by right hemicolectomy (n=31, 18.3%). Colon or
rectal cancer was the primary indication in almost half of
patients (n=79, 46.7%). Diverticular disease accounted for
42.0% of surgical procedures (n=71).
Time to gastrointestinal recovery (GI-3) was significantly
shorter in the bisacodyl group (median 3.0 days [1–12.3];
mean 3.4 days [±1.7] versus median 3.7 days [1.7–10.7];
mean 4.0 days [±1.6], P=0.007). Of the single parameters
Assessed for eligibility 
n = 283 
Randomized 
n = 200 
Excluded n =83 
Did not meet inclusion criteria n 
=43 
Refused to participate n =40 
Allocated to Bisacodyl n = 100 
Received allocated treatment n = 100 
Discontinued study n= 17 
 Intraoperative decision for ileostomy 
/ colostomy n = 12 
 not resected n = 1 
 refused to participate postop n = 2  
 protocol violation n=2 
Allocated to placebo n = 100 
Received allocated treatment n = 100 
Discontinued study n= 14 
 Intraoperative decision for ileostomy 
/ colostomy n = 8 
 not resected n = 2 
 refused to participate postop n = 1 
 protocol violation n=3 
Lost to follow-up n = 0 Lost to follow-up n = 0  






























Fig. 1 Trial profile
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defining the GI-3, there was a significant difference in time
to defecation in favor to the bisacodyl group (median
3.0 days [1–8]; mean 3.1 days [±1.9] versus median
4.0 days [1–8]; mean 4.2 days [±2.1], P=0.001), whereas
no significant difference in time to first flatus or tolerance
of solid food was seen (Table 2). We did not observe any
significant between-group differences among the secondary
endpoints (Table 3). Reinsertion of NGT was necessary in
11 (13.3%) patients treated with bisacodyl compared to 13
(15.1%) with placebo. There was a tendency for longer
duration of NGT reinsertion in the bisacodyl group
(2.8 [±1.3] days versus 1.8 [±0.9] days, P=0.055). In this
subgroup of patients with NGT reinsertion, no significant
differences in baseline characteristics were seen (Table 4).
We distinguished surgical and non-surgical morbidity,
including minor complications such as superficial surgical
site infections and urinary tract infections (Table 5). No
significant difference between groups was noted. Overall
surgical morbidity was 23.1%, whereas non-surgical com-
plications occurred in 13% of all patients.
There was no difference in opioid consumption during
the first eight postoperative days between groups (bisa-
Table 1 Patient characteristics and baseline data
Bisacodyl (n=83) Placebo (n=86) P value
Mean (SD) age (years) 67.9 (±13.2) 66.4 (±14.5) 0.484
Males (%) 42 (50.6) 54 (62.8) 0.122
Comorbidities
COPD (%) 8 (9.6) 10 (11.6) 0.804
Diabetes mellitus (%) 8 (9.6) 10 (11.6) 0.804
Cardiac (%) 7 (8.4) 4 (4.7) 0.365
Diagnosis
Cancer (%) 40 (48.2) 39 (45.4) 0.759
Diverticulosis (%) 34 (41) 37 (43) 0.757
Other (%) 9 (10.8) 10 (11.6) 1.000
Type of surgery
Right hemicolectomy (%) 16 (19.3) 15 (17.4) 0.843
Left hemicolectomy (%) 6 (7.2) 4 (4.7) 0.530
Rectosigmoid resection (%) 49 (59) 54 (62.8) 0.639
Anterior resection (%) 11 (13.3) 7 (8.1) 0.325
Subtotal colectomy (%) 0 1 (1.2) 1.000
Ileocecal resection (%) 1 (1.2) 3 (3.5) 0.621
Segmental resection (%) 0 2 (2.3) 0.497
Mean (SD) duration of surgery (min) 157 (±44.2) 172 (±52.3) 0.046
Open surgery (%) 47 (56.6) 47 (54.6) 0.877
Laparoscopic surgery (%) 29 (34.9) 31 (36.1) 1.000
Conversion (%) 7 (8.4) 8 (9.3) 1.000
Epidural analgesia (%) 51 (61.5) 50 (58.1) 0.754
Median (range) cumulative morphine consumption first 8 days (mg) 12 (0–467) 22.5 (0–486) 0.092
Mean (SD) cumulative morphine consumption first 8 days (mg) 40.2 (±72.3) 59.4 (±90.9)
Mechanical bowel preparation (%) 31 (37.4) 33 (38.4) 1.000
COPD Chronic obstructive lung disease
Table 2 Effect of bisacodyl on gastrointestinal recovery
Bisacodyl (n=83) Placebo (n=86) P value
Median (range) Mean (SD) Median (range) Mean (SD)
GI-3 (days) 3.0 (0.7–12.3) 3.4 (±1.7) 3.7 (1.7–10.7) 4.0 (±1.6) 0.007
First defecation (days) 3.0 (1–8) 3.1 (±1.9) 4.0 (1–8) 4.3 (±2.1) 0.001
First flatus (days) 2.0 (1–7) 1.9 (±1.1) 2.0 (1–7) 2.3 (±1.4) 0.126
First solid food (days) 4.0 (2–30) 5.3 (±3.6) 4.0 (2–23) 5.4 (±3.3) 0.921
GI-3 defined as mean time to occurrence of all three of the following events: first flatus passed, first defecation, and solid food tolerated.
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codyl: median 12 mg [0–467], mean 40 mg [±72];
placebo: median 22.5 mg [0–486], mean 59 mg [±91];
P=0.092). Pain, nausea, and cramping VAS results did not
significantly differ between groups (Fig. 2a–c). Oral
administration of bisacodyl was not associated with any
side effects.
Discussion
In this study, pre- and postoperative administration of
bisacodyl resulted in acceleration of overall gastrointestinal
recovery (GI-3). Defecation occurred significantly earlier in
the bisacodyl group, indicating a direct beneficial effect on
postoperative colonic hypomotility. However, other clini-
cally relevant factors such as time to tolerance of food or
length of hospital stay did not significantly differ. Preop-
erative stimulation with bisacodyl may maintain the
mobility of the colon throughout the surgical procedure,
thus limiting the negative effect of surgery. During recovery
from postoperative ileus, the most significant factor is
colonic motility so that direct pharmacologic stimulation
may play an important role [1, 4, 25, 27]. Huge et al. were
able to demonstrate a decrease of colonic tone in patients
undergoing left colonic surgery on the second and third
postoperative days and a severely impaired colonic motility
after surgery [25]. Steadman et al. found a relaxation of the
descending colon in fasting subjects after administration of
morphine intravenously [28]. These findings substantiate
the importance of colonic stimulation postoperatively, as
many patients will require analgesia with morphine or its
derivates.
Table 3 Incidence and duration of NGT reinsertion, postoperative vomiting, and length of hospital stay
Bisacodyl (n=83) Placebo (n=86) P value
Incidence of NGT reinsertion (%) 11 (13.3) 13 (15.1) 0.827
Mean (SD) duration of NGT reinsertion (days) 2.8 (±1.3) 1.8 (±0.9) 0.055
Incidence of postoperative vomiting (%) 19 (22.9) 22 (25.6) 0.722
Median (range) length of hospital stay (days) 13 (4–92) 13 (6–74) 0.768
Mean (±SD) length of hospital stay (days) 16 (±12) 15 (±19)
Table 4 Basic characteristics








Mean (SD) age (years) 70.5 (±11.5) 68.6 (±10.6) 0.434
Males (%) 9 (81.8) 8 (61.5) 0.122
Comorbidities
COPD (%) 0 1 (7.7) 1.000
Diabetes mellitus (%) 1 (9.1) 4 (30.8) 0.327
Cardiac (%) 1 (9.1) 1 (7.7) 1.000
Diagnosis 0.386
Cancer (%) 9 (81.8) 8 (61.5)
Diverticulosis (%) 2 (18.2) 5 (38.5)
Type of surgery 0.390
Right hemicolectomy (%) 4 (36.4) 3 (23.1)
Left hemicolectomy (%) 1 (9.1) 0
Rectosigmoid resection (%) 4 (36.4) 8 (61.5)
Anterior resection (%) 2 (18.2) 1 (7.7)
Ileocecal resection (%) 0 1 (7.7)
Mean (SD) duration of surgery (min) 154 (±31) 182 (±60) 0.186
Open surgery (%) 8 (72.7) 11 (84.6) 0.630
Conversion (%) 2 (18.2) 2 (15.4) 1.000
Epidural analgesia (%) 7 6 0.444
Median (range) cumulative morphine
consumption first 8 days (mg)
8 (0–163) 64 (0–179) 0.068
Mean (SD) cumulative morphine consumption
first 8 days (mg)
31.1 (±48.2) 70.7 (±61.8)
Mechanical bowel preparation (%) 5 (45.5) 4 (30.8) 1.000
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Morphine consumption during the first 8 days did not
significantly differ. However, patients in the bisacodyl
group had an average of 10 mg more morphine over the
first 8 days, resulting in approximately 1 mg per day. This
very low daily dose is unlikely to have an effect on
gastrointestinal recovery, especially as the median effective
analgesic dose of morphine has been described to be 5 mg
[29]. Cali et al. showed a direct correlation between the
amount of morphine and the return of gastrointestinal
function in patients undergoing colectomy [30]. However,
patients receiving under 25 mg total morphine were found
to have approximately 25 h until normal bowel sounds were
audible, 36 h until first flatus was reported, and 60 h until
first bowel movement was reported. These times are
comparable to the spontaneous resolution of postoperative
ileus after 4–5 days [3–5]. Consequently, the difference of a
total of 10 mg morphine in our study might not have
influenced the gastrointestinal recovery time.
Concerning incidence and duration of NGT reinsertion,
incidence of postoperative vomiting, and length of
hospital stay, no difference between groups was noted.
We found no satisfactory explanation for the tendency for
longer NGT reinsertion in the bisacodyl group. The
analysis of the patients with NGT reinsertion showed no
significant differences between the bisacodyl and placebo
collectives. Notably, the consumption of morphine tended
to be higher in the placebo group. One reason for this
finding might be the fact that three patients in the placebo
subgroup suffered from complications with consecutively
higher and longer need for opioids (abscess in splenic
flexure, anastomotic leakage, postoperative mechanical
ileus). However, the total number in this subgroup of
patients is low, thus limiting the ability to draw definite
conclusions.
The only significantly different intraoperative vari-
able was duration of surgery. We were not able to
explain the mean difference of 15 min between groups.
Neither the type of surgery nor the level of training of
the operating surgeon was different. Gervaz et al.
reported of earlier return of gastrointestinal function if
the procedure was performed by a specialist colorectal
surgeon compared to general surgeons [31]. Unfortu-
nately, there is no mentioning of duration of surgery in
their study. However, the authors mention that more left-
sided colectomies and more difficult cases were operated
by the colorectal surgeon, thus implicating longer proce-
dures. In other studies, no direct relationship between
length of surgical procedure and duration of postoperative
ileus could be demonstrated [32, 33]. We do not believe
that the small difference of 15 min between the collec-
tives had any impact on postoperative gastrointestinal
recovery.
To our knowledge, only one randomized trial evaluated
the effect of colon-stimulating laxatives (bisacodyl) on
postoperative ileus [24]. These authors found a significant
reduction of time to first bowel movement in 46 patients
undergoing appendectomy. Fanning et al. investigated in a
prospective observational study the effects of a combination
of milk of magnesia and bisacodyl suppositories and
reported an earlier return of bowel movements and
shortened hospital stay [23]. However, these authors did
not elaborate which of the agents showed a greater
stimulatory effect.
In the present study, no difference in peri- or postoperative
morbidity was noted. There was a slightly higher anasto-
motic leak rate in the bisacodyl group, however, far from
significance. Bisacodyl had no side effects. The VAS for
cramps, a known possible effect of bisacodyl, did not differ
between groups. The analgesic requirements and VAS for
pain were similar. There was no significant difference in the
amount of opioids administered during the first 8 days
between groups.
Table 5 Surgical and non-surgical morbidity
Bisacodyl (n=83), n (%) Placebo (n=86), n (%) P value
Surgical morbidity
Anastomotic leak 7 (8.4) 4 (4.7) 0.365
Deep surgical site infection 1 (1.2) 2 (2.3) 1.000
Superficial surgical site infection 4 (4.8) 3 (3.5) 0.717
Dehiscence of abdominal fascia 2 (2.4) 0 0.246
Postoperative bleeding 1 (1.2) 1 (1.2) 1.000
Non-surgical morbidity
Pneumonia 5 (6) 1 (1.2) 0.113
Pulmonary embolism 1 (1.2) 0 0.491
Cardiac failure 1 (1.2) 1 (1.2) 1.000
Renal failure 1 (1.2) 1 (1.2) 1.000
Urinary tract infection 3 (3.6) 3 (3.5) 1.000
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Many pharmacologic agents have been evaluated for
their effect on postoperative ileus. Apart from cisapride,
which has been removed from the market, only alvimopan,
a peripherally acting μ opioid antagonist, has shown an
accelerated recovery time [15, 16, 21, 22]. Neither
metoclopramide nor erythromycin altered the course of
postoperative ileus although they may have a role in the
treatment of nausea or impaired stomach emptying due to
pyloric spasm [12, 13, 17, 18, 34, 35]. Other prokinetic
drugs, such as neostigmine, propranolol, or tropisetron, had
no proven effect on postoperative ileus [14, 20, 36, 37].
The pathogenesis of postoperative ileus is multifactorial.
Autonomic dysfunction with increased influence of the
sympathetic system resulting in inhibition of gut motility,
inflammatory response due to surgical trauma, and admin-
istration of opioid drugs are important causes of postoper-
ative gastrointestinal dysfunction [3, 38]. Gentle surgical
technique and the use of minimal invasive techniques
result in lower systemic cytokine levels reflecting a lower
inflammatory reaction [39]. Additionally, laparoscopic
surgery reduces postoperative pain, thus reducing auto-
nomic sympathetic activity. In this study, the proportion of
open and laparoscopic procedures was similar in both
groups (bisacodyl: open surgery in 57%; placebo: 55%,
P=0.877).
Epidural analgesia has been shown to decrease sympa-
thetic response and opioid consumption and consequently
postoperative ileus. Epidural analgesia carries a certain risk
for adverse effects and is not feasible in all patients, for
example those with spondylodesis or severe spondylarth-
rosis, but is currently considered as one of the most
effective methods [1, 40]. The number of patients receiving
a mid-thoracic epidural catheter was similar between the
bisacodyl and placebo groups. At our institution, the
placement of an epidural catheter was discussed with all
patients undergoing colorectal resection, regardless of
technique. We considered previous back surgery, coagul-
opathy, severe spondylarthrosis, and refusal by the patient
as contraindications.
Most multimodal management protocols involve a wide
range of other measures, such as enforced mobilization,
avoidance of drains and NGT, early oral nutrition, and fluid
restriction [10, 34, 35, 41, 42]. A minority of these fast-
track protocols include the use of laxatives, mostly
magnesia, an osmotic agent without colon-stimulating
properties [7, 9, 43, 44]. The inclusion of a colon-
stimulating laxative in rehabilitation programs may confer
additional benefit by decreasing the duration of colonic
hypomotility.
The study has some limitations. Patients were not stratified
according to the method of surgery (laparoscopic or open
resection). Furthermore, postoperative pain management with
or without epidural analgesia was not standardized. However,
the groups did not differ in these items.
In conclusion, the findings of this study suggest that pre-
and postoperative administration of bisacodyl has a
beneficial effect on gastrointestinal recovery after colorectal
resection. Bisacodyl had no influence on time to tolerance
of solid food or length of hospital stay. Colon-stimulating
laxatives might be considered as part of multimodal







































Fig. 2 VAS during the first eight postoperative days: a pain; b
nausea; c cramping. All values are mean (SEM). No significant
difference between the bisacodyl and placebo groups
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